Search Results - "Requena Ibáñez, Juan Antonio"

Cardioprotective Effect of Empagliflozin and Circulating Ketone Bodies During Acute Myocardial Infarction by Santos-Gallego, Carlos G., Requena-Ibáñez, Juan Antonio, Picatoste, Belen, Fardman, Brian, Ishikawa, Kiyotake, Mazurek, Renata, Pieper, Michael, Sartori, Samantha, Rodriguez-Capitán, Jorge, Fuster, Valentin, Badimon, Juan J.

“…SGLT2i (sodium-glucose cotransporter-2 inhibitors) improve clinical outcomes in patients with heart failure, but the mechanisms of action are not completely…”
Get full text

Empagliflozin improves quality of life in nondiabetic HFrEF patients. Sub-analysis of the EMPATROPISM trial by Requena-Ibáñez, Juan Antonio, Santos-Gallego, Carlos García, Rodriguez-Cordero, Anderly, Vargas-Delgado, Ariana Patricia, Badimón, Juan José

“…Initially considered as just anti-diabetic agents, SGLT2-i show remarkable cardiac and renal benefits independently of its hypoglycemic activity. We used the…”
Get full text

Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics by Santos-Gallego, Carlos G., Requena-Ibanez, Juan Antonio, San Antonio, Rodolfo, Ishikawa, Kiyotake, Watanabe, Shin, Picatoste, Belen, Flores, Eduardo, Garcia-Ropero, Alvaro, Sanz, Javier, Hajjar, Roger J., Fuster, Valentin, Badimon, Juan J.

“…Empagliflozin cardiac benefits in the EMPA-REG OUTCOME (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) trial cannot be…”
Get full text

Mechanistic Insights of Empagliflozin in Nondiabetic Patients With HFrEF: From the EMPA-TROPISM Study by Requena-Ibáñez, Juan Antonio, Santos-Gallego, Carlos G, Rodriguez-Cordero, Anderly, Vargas-Delgado, Ariana P, Mancini, Donna, Sartori, Samantha, Atallah-Lajam, Farah, Giannarelli, Chiara, Macaluso, Frank, Lala, Anuradha, Sanz, Javier, Fuster, Valentin, Badimon, Juan José

“…OBJECTIVESThe goal of this study was to evaluate the effect of empagliflozin, in addition to optimal medical treatment, on epicardial adipose tissue (EAT),…”
Get full text

Rationale and Design of the SOTA-P-CARDIA Trial (ATRU-V): Sotagliflozin in HFpEF Patients Without Diabetes by Pérez, Maeve Soto, Rodríguez-Capitán, Jorge, Requena-Ibáñez, Juan Antonio, Santos-Gallego, Carlos G, Urooj Zafar, M, Escolar, Ginés, Mancini, Donna, Mitter, Sumeet, Lam, David, Contreras, Johanna P, Fergus, Icilma, Atallah-Lajam, Farah, Abascal, Vivian, Lala, Anu, Moreno, Pedro, Moss, Noah, Lerakis, Stamatios, Sanz, Javier, Fuster, Valentin, Badimon, Juan José

“…Heart failure with preserved ejection fraction (HFpEF) is now the most common form of heart failure (HF). This syndrome is associated with an elevated…”
Get full text

Per-Protocol Versus Intention-to-Treat in Clinical Trials: The Example of GLOBAL-LEADERS Trial by Santos-Gallego, Carlos G, Requena-Ibanez, Juan Antonio, Badimon, Juan

Get full text

Patent foramen ovale and anticardiolipin antibodies, a strange cause of bilateral kidney infarcion by Pérez Díaz, Pedro, Sánchez de la Nieta García, María Dolores, Piqueras Flores, Jesús, Maseda Uriza, Ramón, Requena Ibáñez, Juan Antonio, Rayo Gutiérrez, Manuel

Get full text

Prolyl Hydroxylase Inhibitors: a New Opportunity in Renal and Myocardial Protection by Requena-Ibáñez, Juan Antonio, Santos-Gallego, Carlos G., Rodriguez-Cordero, Anderly, Zafar, M. Urooj, Badimon, Juan José

“…Hypoxia, via the activity of hypoxia-inducible factors (HIFs), plays a crucial role in fibrosis, inflammation, and oxidative injury, processes which are…”
Get full text

Not only how much, but also how to, when measuring epicardial adipose tissue by Requena-Ibáñez, Juan Antonio, Santos-Gallego, Carlos García, Rodriguez Cordero, Anderly José, Fardman, Brian, Sartori, Samantha, Sanz, Javier, Fuster, Valentin, Badimon, Juan José

“…Epicardial Adipose Tissue (EAT) is drawing increasing attention. As a quantifiable, modifiable, and potentially new cardiovascular therapeutic target, its…”
Get full text

Dual SGLT1 and SGLT2 inhibition: more than the sum of its parts by Sánchez-Muñoz, Enrique, Requena-Ibáñez, Juan Antonio, Badimón, Juan José

Get full text

Foramen oval permeable con anticardiolipina+, una causa rara de infartos renales múltiples by Pérez Díaz, Pedro, Sánchez de la Nieta García, María Dolores, Piqueras Flores, Jesús, Maseda Uriza, Ramón, Requena Ibáñez, Juan Antonio, Rayo Gutiérrez, Manuel

Get full text

SGLT2i in heart failure: can their benefits be expanded across the entire spectrum of ejection fraction? by Requena-Ibáñez, Juan Antonio, Santos-Gallego, Carlos G., Badimón, Juan José

“…The publication of the EMPEROR-Preserved trial and data on the benefits of sodium-glucose cotransporter 2 (SGLT2) inhibitors in patients with heart failure…”
Get full text

Empagliflozin Ameliorates Diastolic Dysfunction and Left Ventricular Fibrosis/Stiffness in Nondiabetic Heart Failure by Santos-Gallego, Carlos G., Requena-Ibanez, Juan Antonio, San Antonio, Rodolfo, Garcia-Ropero, Alvaro, Ishikawa, Kiyotake, Watanabe, Shin, Picatoste, Belen, Vargas-Delgado, Ariana P., Flores-Umanzor, Eduardo J., Sanz, Javier, Fuster, Valentin, Badimon, Juan J.

“…The purpose of this study was to investigate the effect of empagliflozin on diastolic function in a nondiabetic heart failure with reduced ejection fraction…”
Get full text

EMPAGLIFLOZIN INDUCES A MYOCARDIAL METABOLIC SHIFT FROM GLUCOSE CONSUMPTION TO KETONE METABOLISM THAT MITIGATES ADVERSE CARDIAC REMODELING AND IMPROVES MYOCARDIAL CONTRACTILITY by Santos-Gallego, Carlos G., Ibanez, Juan Antonio Requena, Antonio, Rodolfo San, Ishikawa, Kiyotake, Watanabe, Shin, Picatoste Botija, Maria Belen, Salvo, Angel Javier Sanz, Hajjar, Roger, Fuster, Valentin, Badimon, Juan

“…Given that EMPA causes mild, persistent hyperketonemia, we hypothesized that cardiac benefits of EMPA are due to a shift in myocardial fuel metabolism away…”
Get full text

Clinical Prognosis Associated With the Use of Overlapping Stents With Homogenous Versus Heterogeneous Pharmacological Characteristics for the Treatment of Diffuse Coronary Artery Disease by Abellán-Huerta, José, Jurado-Román, Alfonso, Lozano-Ruiz-Poveda, Fernando, López-Lluva, María T., Negreira-Caamaño, Martín, Pérez-Díaz, Pedro, Requena-Ibañez, Juan Antonio, Sánchez-Pérez, Ignacio

“…The clinical impact of percutaneous coronary intervention (PCI) and implantation of overlapping stents (OS) using platforms with the same versus different…”
Get full text

Inhibición dual del SGLT1 y SGLT2: algo más que su suma by Sánchez-Muñoz, Enrique, Requena-Ibáñez, Juan Antonio, Badimón, Juan José

Get full text

High-density lipoprotein cholesterol: a new marker in heart failure by Santos-Gallego, Carlos G., Requena-Ibáñez, Juan Antonio, Badimón, Juan José

Get full text

Functional tricuspid regurgitation and apical hypertrophic cardiomyopathy. Diagnostic and therapeutic strategy regarding a clinical case by Piqueras-Flores, Jesús, Jurado-Román, Alfonso, Pérez-Díaz, Pedro, Maseda-Uriza, Ramón, Hernández-Herra, Germán, Pérez-Martínez, M Ángeles, López-Lluva, María Thiscal, Requena-Ibáñez, Juan Antonio, Frías-García, Raquel, Sánchez-Pérez, Ignacio, Lozano-Ruiz-Poveda, Fernando

Get full text

Mechanistic Insights of Empagliflozin in Nondiabetic Patients With HFrEF by Requena-Ibáñez, Juan Antonio, Santos-Gallego, Carlos G., Rodriguez-Cordero, Anderly, Vargas-Delgado, Ariana P., Mancini, Donna, Sartori, Samantha, Atallah-Lajam, Farah, Giannarelli, Chiara, Macaluso, Frank, Lala, Anuradha, Sanz, Javier, Fuster, Valentin, Badimon, Juan José

Get full text

HDL: un nuevo biomarcador para la insuficiencia cardiaca by Santos-Gallego, Carlos G., Requena-Ibáñez, Juan Antonio, Badimón, Juan José

Get full text